Humberto Bohorquez

TL;DR: In this paper, the authors investigated the impact of intraoperative tissue plasminogen activator (tPA) on outcomes following DCD LT, and concluded that tPA injection into the hepatic artery during DCD transplant reduces ITBSs and improves graft and patient survival without increasing the risk for bleeding.

TL;DR: Using a protocol that includes a thrombolytic therapy, late DCD LT yielded patient and graft survival rates comparable to DBD LT and an historical DCD group to an historical group and a cohort of DBD recipients had better 1‐ and 3‐year graft survival Rates.

TL;DR: A tPA injection into the hepatic artery during DCD LT reduces ITBSs and improves graft and patient survival without increasing the risk for bleeding.

TL;DR: Because T NF-α plays an important role in hepatocyte proliferation, complete inhibition of TNF-α is not desirable in treating liver I/R injury and the strategy for developing pharmacological therapies may be the identification of specific intermediates in the TNF -α/TNFR1 signal transduction pathway and directed targeting of proapoptotic and pronecroptotic events.

TL;DR: The role and timing of liver transplantation still remains debated especially in the management of PFIC1, but in those patients who are appropriately selected, liver transplation offers an excellent survival benefit.